Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies
about
Arbovirus high fidelity variant loses fitness in mosquitoes and miceTurning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3)Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in PatientsStructure of the Antiviral Assembly Inhibitor CAP-1 Complex with the HIV-1 CA ProteinInfluence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies.Deciphering Evolutionary Mechanisms Between Mutualistic and Pathogenic SymbiosesMutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication.Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication.A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity.Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study.HIV-1 Antiretroviral Drug Resistance in Pregnant Women in Jamaica: A Preliminary ReportBhavnani et Al. respond to "assessing mechanistic interaction"Significance of variation within HIV, EBV, and KSHV subtypes.Analysis of selection pressure and mutational pattern of HIV type 1 reverse transcriptase region among treated and nontreated patients.Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1.The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates.Increased G-->A transition frequencies displayed by primer grip mutants of human immunodeficiency virus type 1 reverse transcriptaseResolution of Specific Nucleotide Mismatches by Wild-Type and AZT-Resistant Reverse Transcriptases during HIV-1 Replication.Interrelationship between HIV-1 fitness and mutation rate.Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
P2860
Q24635860-C3B7E5F6-0E9A-4140-A916-FACB100DF0BBQ24645606-E5379E6E-6AAA-40FB-ACA5-B27244C5C30FQ27468616-C195B563-AD07-4527-AEBC-A8993BD55F8AQ27647971-635F9BA6-B51F-43A4-A565-787144CB0A5DQ30453160-ABF8A234-9BCE-4F81-96D0-52B859A7E481Q33490644-479D0EED-EF95-43BF-AC79-3F1DF15FEC93Q33743954-1B0DA5BB-D4A5-4375-A0C2-CA29831A760DQ33987492-8A0444B8-1C4F-4E01-996C-0DED365B403EQ34092679-5E23CD90-7E1C-43DC-B5D6-7032D60B3F07Q34120857-BDFF37A7-8E44-4C10-8E8B-20F137C2E160Q35163547-A4F52A2D-B966-4537-8960-2235958CD72BQ35857522-B54B77EC-8225-4A18-B38C-BC4C6BEF889AQ35962627-72D0EE53-A250-4E95-B441-B83EC194C0AEQ36330927-29DE47AE-F654-4C24-B589-E2A6A7B392B5Q36402179-960E04F4-F6EB-48B8-BA12-D29662B3F72EQ36575166-82DBA947-B161-43AE-B140-9AAFA00F8AD8Q37550353-A38D152E-F53B-4057-9869-919704225841Q38339368-91E8608E-7033-43F9-ABFE-6524955103A3Q39776171-1D28FB98-6078-4157-8EEB-2AA6E4667636Q40675013-97942DD8-C860-42FA-86F6-4F02CBE7F7BDQ40802197-316ADBBD-97D8-4287-A713-4ED5FD4E1AB4Q41888126-09359105-3771-4879-8481-B61C956E2548Q43077557-88269BCB-8377-44A6-9F78-0B65D76400D8
P2860
Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Combination of drugs and drug- ...... irus type 1 mutant frequencies
@en
Combination of drugs and drug- ...... rus type 1 mutant frequencies.
@nl
type
label
Combination of drugs and drug- ...... irus type 1 mutant frequencies
@en
Combination of drugs and drug- ...... rus type 1 mutant frequencies.
@nl
prefLabel
Combination of drugs and drug- ...... irus type 1 mutant frequencies
@en
Combination of drugs and drug- ...... rus type 1 mutant frequencies.
@nl
P2093
P2860
P1433
P1476
Combination of drugs and drug- ...... irus type 1 mutant frequencies
@en
P2093
Dennis K Pearl
Lisa C Gajary
Louis M Mansky
P2860
P304
P356
10.1128/JVI.76.18.9253-9259.2002
P407
P577
2002-09-01T00:00:00Z